Compass Therapeutics Presents Preclinical Data on CTX-10726, a Differentiated PD-1 x VEGF-A Bispecific Antibody, at the 40th Society for Immunotherapy of Cancer (SITC) Annual Meeting

Stock Information for Compass Therapeutics Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Compass Therapeutics Inc.

Compass Therapeutics to Participate in Upcoming December Investor Events
Compass Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Compass Therapeutics to Participate in Upcoming November Investor Events
Compass Therapeutics to Participate in Upcoming September Investor Events
Compass Therapeutics Announces Pricing of Upsized $120 Million Public Offering
Compass Therapeutics Announces Proposed Public Offering
Compass Therapeutics Reports 2025 Second Quarter Financial Results and Provides Corporate Update
Compass Therapeutics to Present Second Quarter Financial Results and Provide Business Update on August 11, 2025

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.